Logo Image
|Articles|January 23, 2014

Shire Appoints Susan Kilsby as Its New Chairman Effective April 2014

Author(s)Melanie Sena

Shire appoints Susan Kilsby as its New Chairman.

Shire has reported that Matthew Emmens will retire as non-executive chairman and Susan Kilsby, chairman of Shire’s Audit, Compliance & Risk Committee, will succeed him after the conclusion of Shire’s AGM on April 29, 2014. Emmens joined the company as chief executive in 2003 and became chairman of Shire in 2008. Kilsby joined the Shire Board as a non-executive director in September 2011. In May 2013, she was appointed chairman of Shire’s Audit, Compliance & Risk Committee. Dominic Blakemore will replace Kilsby’s position as chairman of Shire’s Audit, Compliance & Risk Committee. In addition, Kilsby’s will become a member of Shire’s Nomination Committee, effective February 1, 2014.

Source: Shire

Related to this article

View more
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
Read more
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.
Read more